article · Expert Opinion on Pharmacotherapy
In patients with stable CAD requiring OAC, OAC monotherapy significantly reduces bleeding and improves net clinical benefit without increasing ischemic risk. These findings support OAC monotherapy, particularly with DOACs, as the preferred long-term strategy, especially in East Asian populations.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/14656566.2025.2610371
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
